AzTrials
AzTrials

DiabetesChina-JDNCT01274364

Establishing a Diabetes Registry Using the JADE-DIAMOND Electronic Portal (CN001)

A study testing JADE and DIAMOND in people with Diabetes, run by Asia Diabetes Foundation at 1 site in Hong Kong.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Quality diabetes care requires a team approach and informed decisions of patients and care providers. Several lines of evidence suggests that a protocol-driven care model delivered by trained staff with focus on periodic assessments, reinforcement of patient compliance and attainment of multiple treatment targets… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Diabetes
What is being tested?
JADE and DIAMOND
Could I receive a placebo?
No, everyone receives an active treatment
How many people
3,586 participants
Where
1 siteHong Kong
Study dates
Jan 2010to Dec 2013
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Type 2 diabetic patients attending hospitals or affiliated clinics led by PIs of the JADE Program who are living in the area with an intention to have 'regular' follow-up
  • Aged >18 years
  • Patients can have newly diagnosed or established disease, treated with lifestyle or blood glucose lowering drugs including oral agents with or without insulin
  • For newly diagnosed type 2 diabetic patients, their plasma glucose levels should be: a) Fasting plasma glucose (PG) >7.0 mmol/L on 2 or more occasions, and/or b) Random (or post-OGTT 2h) PG >11.1 mmol/L on 2 or more occasions, and/or c) HbA1c >6.5%

Who cannot join

  • Type 1 diabetes defined as a history of ketosis at diagnosis [acute symptoms with heavy ketonuria (>3+) or ketoacidosis] or continuous requirement of insulin within one year of diagnosis
  • Patients with reduced life expectancy (e.g. less than 6-months) due to recent diagnosis of advanced cancers (e.g. within last 2 years) and other life threatening conditions
  • Patients with a mental condition rendering them unable to understand the nature, scope, and possible consequences of the study
  • Patients actively enrolled in another intervention study
  • Patients who are unwilling to return for regular follow up

Trial locations and contacts

1 site in 1 country.

Hong Kong1 site
  • Asia Diabates Foundation

    Shatin

Other trials in Hong Kong

About this study

Official title: China-JD Program: A Multi-centre Demonstration Project to Evaluate the Effectiveness and Acceptability of the Joint Asia Diabetes Evaluation (JADE) and DIAbetes MONitoring Database (DIAMOND) Programs in Asian Type 2 Diabetic Patients

Quality diabetes care requires a team approach and informed decisions of patients and care providers. Several lines of evidence suggests that a protocol-driven care model delivered by trained staff with focus on periodic assessments, reinforcement of patient compliance and attainment of multiple treatment targets reduces risk of cardio-renal complications and early death in type 2 diabetes.

The investigators hypothesize that the use of state of the art information technology to record, manage and analyze the large amount of clinical information generated during various consultation visits will improve the effectiveness and efficiency in implementing these care protocols through decision support and regular feedback to both patients and care team.

Read the detailed description

Diabetes is now a pandemic disease affecting 5-10% of global population. More than 60% of affected people will come from Asia with the number expected to increase from 85 million in 2005 to 132 million in 2010 in Asia alone. On average, diabetes reduces life expectancy by 10-12 years. While stroke, heart disease and kidney failure account for more than 50% of global deaths, 30-50% of patients with these conditions have diabetes as a major contributing factor. In contrast to the West, the main increase in diabetes prevalence in Asia will occur in the young to middle aged population. On average, 17 million people die from stroke and heart disease on a yearly basis. Of these, 11 million occur in Asia, affecting many young parents and economically active people.

Despite their devastating nature, many diabetic complications can be prevented and managed effectively to preserve health, reduce disabilities and improve quality of life. However, there are multiple barriers in the implementation of quality diabetes care. These include insufficient knowledge base of health care professionals, fragmented nature of health care systems, lack of reimbursement for outpatient procedures including therapeutic patient education, poor compliance to treatment in part due to the silent nature of diabetes and associated complications as well as the complex nature of care protocols. The latter include periodic evaluation of clinical and laboratory parameters and the need for people with diabetes to adhere to long term medications and self care.

While optimal management of risk factors and treatment to targets can substantially reduce the risk of diabetes associated complications, the challenge lies in the effective translation of this evidence to clinical practice. Since mid 1990s, inspired by the benefits of structured care, made possible during the conduct of clinical trials, the CUHK Diabetes Care \& Research Group has developed prototypes of structured care protocols including an annual comprehensive assessment using a doctor-nurse-physician assistant team. Consistent with international data, these prototypes substantially improve rates of treatment compliance and attainment of multiple treatment targets resulting in reduced death and cardio-renal complication rates.

The Joint Asia Diabetes Evaluation (JADE) Program is a web-based disease management program conceptualized, developed and tested by the Asia Diabetes Foundation (ADF) since 2007, supported by a MSD educational grant. The objectives of the JADE Program include:

  1. to promote collective learning and sharing of best practices in diabetes based on regionally relevant evidence
  2. to increase regional awareness about the magnitude of diabetes and its preventable nature through education, ongoing data collection and implementation of evidence-based guidelines
  3. to establish a regional diabetes registry
  4. to collect the evidence base to inform relevant stakeholders including public, people with diabetes, health care professionals, policy makers and payors to change policies and practices in order to make quality diabetes care accessible, sustainable and affordable.

Using state of the art information technology, the JADE and DIAMOND electronic portal provides a virtual platform to enable care professionals to record, manage and analyse the large amount of information collected during various consultation visits. The Programs also incorporate risk equations developed and validated by the CUHK Diabetes Care \& Research Group to help doctors assess their patients' future event rates. This information, displayed in charts and trend lines, can be communicated to patients and doctors to motivate behavioral changes and encourage dialogues to set treatment goals.

Apart from providing templates for documentation of risk factors and complications using standardized protocols, the JADE Program also incorporates different evidence-based care protocols with recommendations on follow up schedules and care processes in accordance to the patient's risk profile. Decision support in terms of prompts, charts, trend lines and practice tips are used to help doctors and patients to make informed decisions and to optimize care. The JADE Program also possesses matrixes which enable care providers to track clinical progress and risk factor control for benchmarking and quality improvement purposes. On the other hand, the DIAMOND Program provides the first step to entry of a quality assurance program by establishing a diabetes registry at a clinic level. The ongoing collection of these data provides an invaluable platform for collaborative epidemiological and interventional studies pertinent to Asian populations.

In this multicentre study, we shall use a trio team consisting of a trained doctor, nurse and physician assistant (PA) to deliver protocol-driven diabetes care using a web-based disease management program, the Joint Asia Diabetes Evaluation (JADE) Program. To fully realize the functionality of the JADE Program requires changes in the practice environment and deployment of additional manpower (e.g. a nurse and a PA) to enter data and provide reminders to patients and doctors to improve adherence to protocols. In settings where these changes may not be immediately possible, periodic comprehensive assessment using the structured template in the JADE Program allows recognition of risk factors and complications for early intervention. The latter will allow data collected in a systematic manner which forms the basis of a DIAbetes MONitoring Database (DIAMOND) as a first step towards quality assurance.

After explanation by trained doctors and nurses and with written informed consent, patients will be randomized to either the JADE or DIAMOND Program. The former encompasses all components of the structured care delivered by a trio-team of doctor, nurse and PA while the DIAMOND Program only consists of comprehensive assessments at baseline and 12-month with patients managed in the usual manner thereafter. At the end of 12 months, all patients will undergo repeat comprehensive assessments for comparison of rates of attainment of treatment targets, behavioral changes, quality of life and default rates.

Aims of the study:

  1. To evaluate the reach, adoption and acceptability of the JD Program by patients and health care team;
  2. To compare the effectiveness of the JADE (structured care) versus DIAMOND (usual care) Programs in attainment of treatment targets, improvement of quality of life and changes in behaviors;
  3. To document the pattern of complications, risk factors, use of medications and quality of life in type 2 diabetic patients

Study sites:

  1. Beijing People's Hospital, Beijing
  2. Peking Union Hospital, Beijing
  3. 1st Hospital, Peking University Hospital, Beijing
  4. China-Japan Friendship Hospital, Beijing
  5. Shanghai Sixth People's Hospital, Shanghai
  6. Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou
Conditions
Diabetes
Being tested
JADE, DIAMOND
Keywords
Diabetes, Structured Care
Medical subject headings
Diabetes Mellitus

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • JADEOther

    Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will receive protocol-driven diabetes care using a web-based disease management program (JADE), delivered by a trio-team comprising of a trained doctor, nurse and physician assistant.

  • DIAMONDOther

    Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will be managed according to 'usual care' procedures.

Study groups in NCT01274364
Study groupRoleWhat they receive
JADEExperimentalPatients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will receive protocol-driven diabetes care using a web-based disease management program (JADE), delivered by a trio-team comprising of a trained doctor, nurse and physician assistant.
Receives: Other: JADE
DIAMONDActive comparatorPatients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will be managed according to 'usual care' procedures.
Receives: Other: DIAMOND

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of patients who attain 2 or more of the 'ABC' targets

    Percentage of patients who attain 2 or more of the following 3 targets:

    • HbA1c <7%
    • BP <130/80 mmHg
    • LDL cholesterol <2.6 mmol/L

    Measured: 12 months

Secondary outcomes (6)
  1. New onset of all diabetes-related endpoints

    This includes;

    • cardiovascular endpoints (acute myocardial infarction, revascularisation procedures, heart failure or unstable angina or arrhythmia requiring hospital admissions, lower extremity amputation or foot ulcers)
    • chronic kidney disease (eGFR<60 ml/min/1.73m2) and end stage renal disease (dialysis and/or eGFR<30 ; ml/min/1.73m2)
    • visual impairment (corrected visual acuity of 20/200 or lower) or eye surgery;
    • cancer
    • any hospitalization due to complications related to diabetes and/or its treatment (such as hypoglycaemic attacks)
    • death

    Measured: 12 months

  2. Quality of Life

    Measured: 12 months

  3. Frequency of hypoglycaemia (in the last 3 months)

    Measured: 12 months

  4. Behavioral changes (in the last 3 months)

    1. Frequency of Self Blood Glucose Monitoring
    2. Adherence to balanced eating
    3. Adherence to regular exercise
    4. Adherence to recommended procedures (e.g. return for blood tests or education classes)

    Measured: 12 months

  5. Number of hospitalizations, follow up visits by doctors and other care professionals

    Measured: 12 months

  6. Default rates at end of study

    Measured: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Jan 2011 (estimated)
  2. Study startJan 2010
  3. Primary completionDec 2013
  4. Study completionDec 2013

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
3,586 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01274364
Sponsor's protocol ID
CRE-2010-112
Acronym
China-JD
Status last verified
Mar 2015
First submitted
9 Jan 2011
Last updated
5 Mar 2015
Results posted
No
Data monitoring committee
Yes

Publications

  • Tutino GE, Yang WY, Li X, Li WH, Zhang YY, Guo XH, Luk AO, Yeung RO, Yin JM, Ozaki R, So WY, Ma RC, Ji LN, Kong AP, Weng JP, Ko GT, Jia WP, Chan JC; China JADE Study Group. A multicentre demonstration project to evaluate the effectiveness and acceptability of the web-based Joint Asia Diabetes Evaluation (JADE) programme with or without nurse support in Chinese patients with Type 2 diabetes. Diabet Med. 2017 Mar;34(3):440-450. doi: 10.1111/dme.13164. Epub 2016 Jul 11.

    PubMed 27278933

Questions about this trial

What is this clinical trial studying?

A study testing JADE and DIAMOND in people with Diabetes, run by Asia Diabetes Foundation at 1 site in Hong Kong.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 5 Mar 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of patients who attain 2 or more of the 'ABC' targets (time frame: 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01274364, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Mar 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in